American pharmaceutical giant Johnson & Johnson (JNJ) is boosting its U.S. investments by 25% to more than $55 billion over ...

Copycat versions of Eli Lilly's diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They're ...

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

The Danish drugmaker had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026. The active ...

Eli Lilly (LLY) stock in focus as the company launches its weight loss therapy Mounjaro in India, beating its rival Novo Nordisk (NVO). Read more here.

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing increased threats after a UnitedHealth insurance executive was murdered outside ...

In this article, we are going to take a look at where Eli ... Lilly announced it plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical ...

Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier. Ricks' payout included $19.7 million in ...

(RTTNews) - Eli Lilly and Co. (LLY ... continues to show a consistent safety profile with no new safety concerns, the company said. LLY is currently trading at $905.91 down 0.75 percent or ...

Earlier this week, Eli Lilly partnered ... “We commend Lilly’s initiative to offer more accessible solutions for obesity treatment with the recent launch of the new Zepbound Self Pay Journey ...